PipelineReview.com

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, CA, USA I July 30, 2025 I EuMentis Therapeutics, Inc., (“EuMentis”), a clinical-stage drug development company focused on advancing ...
PipelineReview.com

FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers

LOS ANGELES, CA, USA I July 30, 2025 I Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced ...
PipelineReview.com

IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right

MOUNTAIN VIEW, CA, USA I July 01, 2025 I IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that ...
PipelineReview.com

Lomond Therapeutics announces U.S. FDA clearance of IND application for lonitoclax, a selective Bcl2 inhibitor with limited immune suppression and improved safety compared to ...

DOVER, DE, USA I June 20, 2025 I Lomond Therapeutics Holdings, Inc. (“Lomond Therapeutics”), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class ...
PipelineReview.com

Genentech Provides Update on Phase III Verona Study

SOUTH SAN FRANCISCO, CA, USA I June 16, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) ...
PipelineReview.com

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

TEL AVIV, Israel and SHANGHAI, China I June 16, 2025 I Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, SSE: 600196, HKEX: ...
PipelineReview.com

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

BOTHELL, WA, USA I May 29, 2025 I Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong ...
PipelineReview.com

FDA Approves Genentech’s Susvimo for Diabetic Retinopathy

– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative technology via ...
PipelineReview.com

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

NEW YORK, NY, USA I May 19, 2025 I Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...
PipelineReview.com

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

SAN RAFAEL, CA and BOSTON, MA, USA I May 16, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announced today that BioMarin has entered into a definitive ...
PipelineReview.com

STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab), following approval by the U.S. Food and ...
PipelineReview.com

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I December 02, 2024 I Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length ...